Hexarelin
A growth hormone secretagogue and ghrelin-receptor agonist that remains a familiar legacy name in GH-peptide stacks.
Also appears in: Hormone
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Hexarelin crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: GH axis. Also surfaces under Hormone for browsing and discovery.
No major aliases are tracked for this profile yet.
No FDA label signal · 0 trials · 290 PubMed results
Current evidence for Hexarelin is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Hexarelin has no clinical trials that name it and 290 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What hexarelin is
Hexarelin is a growth hormone secretagogue and ghrelin-receptor agonist that predates many of the newer GH-related peptide stacks now discussed online.
Why it matters
It belongs in the library because it is still a recognizable legacy name alongside compounds like GHRP-2, GHRP-6, and ipamorelin.
Regulatory context
Hexarelin is not FDA approved for routine consumer therapeutic use in the United States. It fits best in the research-market category.
Practical reading note
Hexarelin helps show the older side of the GH-secretagogue ecosystem, which is useful context when newer peptides get marketed as if they appeared from nowhere.